Preface nScope and aims of the volumenEGF receptor signaling: issues and challenges (W. Gullick, J. Haley)nSection I: EGFR Signaling NetworksnChapter 1: EGF receptor family extracellular domain structures and functions (Antony Burgess, Thomas Garrett)nChapter 2: EGF receptor heterodimerization and activation (Howard Stern)nChapter 3: Structure-function of EGFR kinase domain and inhibitors (Charles Eigenbrot)nChapter 4: Internalization and degradation of EGF receptor (Alexander Sorkin)nChapter 5: Differential dependence of EGFR and ErbB2 on the molecular chaperone Hsp90 (Wanping Xu, Len Neckers)nChapter 6: Activation of STATs 3 and 5 through the EGFR Signaling Axisâ (Priya Koppikar, Jennifer Rubin Grandis)nChapter 7: The intersection of EGFR and Ras signaling pathways (Marie Wislez, Jon Kurie)nChapter 8: Phosphoinositide 3-kinase enzymes as downstream targets of the EGF receptor (Jan Domin)nChapter 9: Convergence of EGF Receptor and Src Family Signaling Networks in Cancer(Jessica E. Pritchard, Allison B. Jablonski, Sarah J. Parsons)nChapter 10: Molecular Crosstalk between E-cadherin and EGFR Signaling Networks (Julie Gavard, J. Silvio Gutkind)nChapter 11: Crosstalk between insulin-like growth factor (IGF) and epidermal growth factor (EGF) receptors (Marc Becker, Douglas Yee)nChapter 12: Negative regulation of signaling by the EGFR family (Kermit L. Carraway III, Lily Yen, Ellen Ingalla, Colleen Sweeney)nChapter 13: Nuclear ErbB receptors: Pathways and functions (Hong-Jun Liao, Graham Carpenter) nChapter 14: Temporal dynamics of EGF receptor signaling by quantitative proteomics (Blagoy Blagoev, Irina Kratchmarova, Jesper V. Olsen, Mathias Mann)nChapter 15: Computational and Mathematical Modeling of the EGFR SignalingnSystem (Colin Johnson, Emmet McIntyre, William Gullick)nSection II: EGFR in Tumorigenesis and EGFR Tyrosine KinaseInhibitors in Cancer TherapynChapter 16: Expression and prognostic significance of EGFR in solid tumors (Nicola Normanno, Caterina Bianco, Antonella De Luca, Luigi Strizzi, Marianna Gallo, Mario Mancino, David S. Salomon)nChapter 17: Signalling by EGF receptor in human cancers: Accentuate the positive, eliminate the negative (Haley L. Bennett, Tilman Brummer, Paul Timpson, Kate I. Patterson, Roger J. Daly)nChapter 18: EGFR in invasion, metastasis and angiogenesis (Carol Box, Joanna Peak, Susanne Rogers and Suzanne Eccles)nChapter 19: Constitutive activation of truncated EGF receptors in glioblastoma (Carol J. Wikstrand, Darell D. Bigner)nChapter 20: EGFR Mutations, Other Molecular Alterations Related To Sensitivity to EGFR Inhibitors, and Molecular Testing for EGFR-Targeted Therapies in Non-Small Cell Lung Cancer (David A. Eberhard)nChapter 21: Crosstalk Between COX-2 and EGFR: A Potential Therapeutic Opportunity (Andrew Dannenberg, Kotha Subbaramaiah)nChapter 22: Cellular sensitivity to EGF receptor inhibitors (Stuart Thomson, John D. Haley, Robert Yauch)nChapter 23: Utilizing combinations of molecular targeted agents to sensitize ntumor cells to EGFR inhibitors (Elizabeth Buck, Alexandra Eyzaguirre, Kenneth K. Iwata)
The epidermal gro wth factor (EGF ) receptor and its downstream signal transduction networks have been implicated in the ontology and maintenance of tumor tissues, which has motivated the discovery and development of molecularly targeted anti-EGF receptor therapies. Over decades of study, the EGF receptor structure, its ligand binding domains, the physical biochemistry underlying its intrinsic tyrosine kinase catalytic function and the modular interactions with SH2, PTB, and SH3 domain containing signaling adaptor p- teins required for signal transduction, have been extensively dissected. Not only is the EGF receptor the nexus of many streams of information, but it also forms one part of a calcul- ing device by forming dimers and oligomers with the other three receptors in its family in response to at least eleven ligands (some of which are expressed in multiple forms with overlapping or quite distinct functions). This phenomenon, while recruiting to the inner surface of the cell membrane and activating multiple second messenger proteins, also allows the possibility of cross talk between these systems, permitting a further layer of information to be exchanged. Less well described are the cross re gulation of the EGF receptor and other anti-apoptotic, mitogenic and metabolic signaling systems. The study of these systems has yielded new surprises. One hurdle in these efforts has been that signal transduction pathways have frequently been defined in the generic absence of their tissue-specific or cell-interaction specific context.
Probes the molecular pathways and the intersection of signaling networks which are frequently deregulated in human cancers
Describes EGF receptor in a tumor tissue specific context
Illustrates the many ways in which EGF receptors contribute to abnormal survival and migration signaling in cancer cells and to epithelial-to-mesenchymal transition and metastasis